KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for elderly lung cancer patients: targeted pill shows promise
Disease control OngoingThis study tests a daily pill called adagrasib in 68 patients with advanced lung cancer that has a specific KRAS mutation. It focuses on people aged 70 or older, or those with poor physical health, who have already tried other treatments. The goal is to see if the drug can shrink…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
Blood samples may reveal why KRAS drugs fail
Knowledge-focused OngoingThis study collects blood samples from up to 500 adults with KRAS G12C cancer whose current treatment has stopped working. Researchers will analyze the samples to find genetic changes that cause resistance to KRAS inhibitors like sotorasib and adagrasib. No new treatment is given…
Matched conditions: KRAS P.G12C
Sponsor: Addario Lung Cancer Medical Institute • Aim: Knowledge-focused
Last updated May 17, 2026 08:02 UTC